Showing results (131-140 of 201) with videos related to
Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2010
The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemiaDong Hwan Dennis Kim, Jee Hyun Kong, Ji Young Byeun, et al.European Journal of Haematology|October 4, 2021
Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell graftsIgor Novitzky-Basso, Mats Remberger, Carol Chen, et al.European Journal of Haematology|April 28, 2017
Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up dataMarc Poch Martell, Nada Hamad, Elizabeth Shin, et al.Bone Marrow Transplantation|November 21, 2019
Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantationSamantha J Mayo, Hans A Messner, Sean B Rourke, et al.Blood|August 15, 2002
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignanciesStephen Couban, David R Simpson, Michael J Barnett, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 19, 2020
Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unitAlexander Js Bacopoulos, Lina Ho, Anjie Yang, et al.Cancer|February 21, 2008
Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiationArwa Abdelhameed, Gregory R Pond, Nicholas Mitsakakis, et al.Blood|October 14, 2016
Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapyTaeHyung Kim, Marc S Tyndel, Hyeoung Joon Kim, et al.The New England Journal of Medicine|January 26, 2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host diseaseAndrew J Ullmann, Jeffrey H Lipton, David H Vesole, et al.Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinibJorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.Pageof 21